RJA
BVS icon

Raymond James & Associates’s Bioventus BVS Stock Holding History

Raymond James & Associates’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$137K Buy
+11,498
New +$99.4K ﹤0.01% 3738
2022
Q3 		– Sell
-101,473
Closed -$692K – 3966
2022
Q2 		$692K Buy
101,473
+10,076
+11% +$103K ﹤0.01% 2704
2022
Q1 		$1.29M Buy
91,397
+9,565
+12% +$128K ﹤0.01% 2426
2021
Q4 		$1.19M Buy
81,832
+5,138
+7% +$73K ﹤0.01% 2509
2021
Q3 		$1.09M Buy
76,694
+25,262
+49% +$389K ﹤0.01% 2527
2021
Q2 		$905K Buy
+51,432
New +$829K ﹤0.01% 2655

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JIC
Juniper Investment Company New York $313M AUM 79.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's BVS Position: Q3 2024 in Review

Raymond James & Associates opened a new position in Bioventus (BVS) in Q3 2024: 11,498 shares worth $137K. The stake represents ﹤0.01% of the portfolio and ranks #3738 among its holdings. This is a return to the name: Raymond James & Associates previously reported a position in BVS as recently as Q2 2022.

Raymond James & Associates first reported a position in BVS in Q2 2021 and has held it in 6 quarters since. The position peaked at $1.29M in Q1 2022. 138 funds tracked by Wall St. Rank hold BVS as of Q3 2024.

  • Raymond James & Associates held 11,498 shares of Bioventus worth $137K as of Q3 2024.
  • Bioventus was a new Raymond James & Associates position in Q3 2024.
  • Bioventus made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3738 holding.
  • Raymond James & Associates first reported a position in Bioventus in Q2 2021 and has held it in 6 quarters since.
  • Raymond James & Associates's Bioventus position peaked at $1.29M in Q1 2022.
  • 138 funds tracked by Wall St. Rank held Bioventus as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.